scholarly journals Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy

2005 ◽  
Vol 16 (3) ◽  
pp. 389-396 ◽  
Author(s):  
R. Arriagada ◽  
M.G. Lê ◽  
M. Spielmann ◽  
L. Mauriac ◽  
J. Bonneterre ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Early Breast Cancer ◽  
Ovarian Suppression ◽  
Premenopausal Patients

scholarly journals The Institute of Cancer Research, Clinical Trials and Statistics Unit (ICR-CTSU)

2006 ◽  
Vol 9 (S1) ◽  
pp. 305-329
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Early Breast Cancer ◽  
Hormone Replacement ◽  
List Type ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by The Institute of Cancer Research, Clinical Trials and Statistics Unit (ICR-CTSU). Clinical trials include: The NCRI Adjuvant Breast Cancer (ABC) trial. ISRCTN31514446The UK randomized trial of hormone replacement therapy (HRT) in women with a history of early stage breast cancer. ISRCTN29941643NCRI Standardisation of Breast Radiotherapy (START) trial. ISRCTN59368779TACT: A randomized trial of standard anthracycline-based chemotherapy (fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF)) versus FEC followed by sequential docetaxel in women with early breast cancer. ISRCTN 79718493SoFEA: Study of Faslodex with or without concomitant Arimidex versus Exemestane following progression on non-steroidal Aromatase inhibitors. ISRCTN: 44195747TACT2: Trial of accelerated adjuvant chemotherapy with Capecitabine in early breast cancer. ISRCTN68068041FAST trial: Prospective randomized clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control.IMPORT low trial.IMPORT high trial.Adjuvant chemotherapy in older women (ACTION).

scholarly journals Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer

1991 ◽  
Vol 63 (5) ◽  
pp. 799-803 ◽  
Author(s):  
AR Bianco ◽  
L Del Mastro ◽  
C Gallo ◽  
F Perrone ◽  
E Matano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Prognostic Role ◽  
Premenopausal Patients

scholarly journals Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial

2005 ◽  
Vol 97 (23) ◽  
pp. 1724-1733 ◽  
Author(s):  
Marco Venturini ◽  
Lucia Del Mastro ◽  
Enrico Aitini ◽  
Editta Baldini ◽  
Cinzia Caroti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Breast Cancer Patients ◽  
Dose Dense

scholarly journals Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer

2019 ◽  
pp. 87-91
Author(s):  
L. K. Ovchinnikova ◽  
A. D. Belko
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Early Breast Cancer ◽  
Premenopausal Women ◽  
Gnrh Agonists ◽  
Complex Treatment ◽  
Efficacy And Safety ◽  
Ovarian Suppression ◽  
Premenopausal Patients ◽  
Positive Breast Cancer

Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castration and radiation-based treatment of the ovaries in patients with hormone-positive early breast cancer. Today, several drugs authorised for the treatment of breast cancer are used in clinical practice: goserelin, buserelin and triptorelin. Buserelin-depo is an effective method for achieving ovarian suppression. The results obtained do not differ from similar indicators obtained in using imported LHRH analogues.

scholarly journals Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen

2002 ◽  
Vol 13 (9) ◽  
pp. 1378-1386 ◽  
Author(s):  
R. Arriagada ◽  
M. Spielmann ◽  
S. Koscielny ◽  
T. Le Chevalier ◽  
T. Delozier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Early Breast Cancer ◽  
Patterns Of Failure

Gene Expression Assay in the Management of Early Breast Cancer

2020 ◽  
Vol 27 (17) ◽  
pp. 2826-2839 ◽  
Author(s):  
Roberta Caputo ◽  
Daniela Cianniello ◽  
Antonio Giordano ◽  
Michela Piezzo ◽  
Maria Riemma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Decision Making ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Treatment Decision ◽  
Endocrine Treatment ◽  
Expression Ratio ◽  
Treatment Decision Making ◽  
Low Sensitivity

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).

Sign in / Sign up

Export Citation Format

Share Document